(0.14%) 5 315.48 points
(0.20%) 39 986 points
(0.10%) 16 759 points
(0.69%) $79.17
(3.39%) $2.50
(-0.40%) $2 385.40
(0.59%) $29.91
(-0.31%) $1 066.80
(0.13%) $0.920
(0.29%) $10.70
(0.08%) $0.789
(0.16%) $90.83
@ $3.99
Issued: 6 Feb 2024 @ 09:45
Return: -69.17%
Live Chart Being Loaded With Signals
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy...
Stats | |
---|---|
Today's Volume | 44 015.00 |
Average Volume | 852 001 |
Market Cap | 3.02M |
EPS | $0 ( 2023-08-07 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.00800 (0.65%) |
Volume Correlation
SciSparc Ltd. Correlation
10 Most Positive Correlations | |
---|---|
MXIM | 0.937 |
ORPH | 0.935 |
RGF | 0.93 |
RETO | 0.929 |
APTO | 0.924 |
QLGN | 0.923 |
NDLS | 0.922 |
PRTS | 0.92 |
CFRX | 0.919 |
BIVI | 0.917 |
10 Most Negative Correlations | |
---|---|
ACQR | -0.942 |
MLAI | -0.94 |
KAII | -0.94 |
TBSA | -0.939 |
MCAA | -0.938 |
NVSA | -0.937 |
FTAA | -0.936 |
AHRN | -0.936 |
FRSG | -0.935 |
SCOB | -0.934 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
SciSparc Ltd. Correlation - Currency/Commodity
SciSparc Ltd. Financials
Annual | 2023 |
Revenue: | $2.88M |
Gross Profit: | $2.20M (76.28 %) |
EPS: | $-12.55 |
FY | 2023 |
Revenue: | $2.88M |
Gross Profit: | $2.20M (76.28 %) |
EPS: | $-12.55 |
FY | 2022 |
Revenue: | $1.35M |
Gross Profit: | $1.03M (76.10 %) |
EPS: | $-14.73 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.160 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
SciSparc Ltd.
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators